title: Amyloid Cascade into Clarity.
abstract: In a recent issue of Nature, Sevigny et al. (2016) report findings from a phase 1b clinical trial of aducanumab (a monoclonal antibody targeting misfolded amyloid-β peptides), revitalizing the "amyloid cascade hypothesis" and bringing mononuclear phagocytes center stage in the treatment of Alzheimer's disease.
authors.affiliation: Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, 1501 San Pablo Street, Room 321, Los Angeles, CA 90089-2821, USA.
authors.forename: Tara M
authors.initials: TM
authors.lastname: Weitz
authors.affiliation: Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, 1501 San Pablo Street, Room 321, Los Angeles, CA 90089-2821, USA. Electronic address: ttown@usc.edu.
authors.forename: Terrence
authors.initials: T
authors.lastname: Town
mesh_terms: D000818:Animals; D006801:Humans; D000544:Alzheimer Disease / Q000188:drug therapy / Q000378:metabolism; D000682:Amyloid / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D010586:Phagocytes / Q000187:drug effects / Q000378:metabolism
chemical_list: C000600266:aducanumab; D000682:Amyloid; D016229:Amyloid beta-Peptides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized